Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Benjamin Birkner"'
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0226754 (2020)
OBJECTIVE:Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bD
Externí odkaz:
https://doaj.org/article/ec084bbf10be4bbea5c07fa3a5a40358
Publikováno v:
Rheumatology. 62:1476-1484
Objective We aim to provide real-world evidence on the effectiveness of patient-individual tapering of DMARDs for patients with RA in daily clinical practice using medical records and claims data. Methods We utilize data obtained through a controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea6ad72343c1e2458b124a4d7993a36
https://doi.org/10.1093/rheumatology/keac472
https://doi.org/10.1093/rheumatology/keac472
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0226754 (2020)
PLoS ONE
PLoS ONE
Objective Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e67388224af9579de8ffe750f0daec89
https://opus4.kobv.de/opus4-fau/files/14272/Birkner_cost-utility.pdf
https://opus4.kobv.de/opus4-fau/files/14272/Birkner_cost-utility.pdf
